Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and a year-to-date gross margin of about 35%.

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and a year-to-date gross margin of about 35%. The company increased its full-year 2026 AUCATZYL sales guidance to $140–$150 million, up from prior guidance of $120–$135 million.

Autolus highlighted that Q2 2026 AUCATZYL sales grew about 70% versus Q1 2026 and more than 100% versus Q2 2025, supported by higher utilization at existing treatment centers and new centers coming online. Gross margin improved from roughly -20% in the second half of 2025 to about 35% in the first half of 2026.

The company also entered a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. An initial $75 million tranche closed on July 30, 2026, with an additional $25 million available for up to six months and up to $150 million more contingent on revenue milestones. The facility bears interest at one-month SOFR (with a 3.50% floor) plus 7.25%. Autolus issued Perceptive a warrant to purchase up to 3.5 million ADSs at $1.9314 per ADS. The first two tranches, totaling $100 million, together with existing cash, are expected to fund operations into Q2 2028.

Positive

• Preliminary Q2 2026 AUCATZYL revenue approximately $45 million
• FY 2026 AUCATZYL sales guidance raised to $140–$150 million from $120–$135 million
• AUCATZYL sales growth about +70% vs Q1 2026 and >100% vs Q2 2025
• Gross margin improvement from roughly -20% in H2 2025 to about 35% in H1 2026
• Credit facility capacity up to $250 million over five years
• Runway first $100 million plus cash expected to fund into Q2 2028

Negative

• Debt cost interest set at one-month SOFR (min 3.50%) plus 7.25% per annum
• Potential dilution from warrant to purchase up to 3.5 million ADSs at $1.9314

Argus Aug 3 session 72 alerts

+22.15% close to close 10.5x rel. volume Open Argus

Details

News Market Reaction – AUTL

+34.2% Peak in 3 hr 42 min

$568.44M Market Cap

In the Aug 3 session, AUTL gained 22.15%, reflecting a significant positive market reaction. Argus tracked a peak move of +34.2% during that session. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 10.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +22.1% in the session following this news. 1061494 produced a 3.03% 24-hour reactio...

Analysis

The stock surged +22.1% in the session following this news. 1061494 produced a 3.03% 24-hour reaction after Autolus reported clinical data. This announcement adds preliminary commercial metrics and financing access, while the active S-3 shelf permits up to $150,000,000 of securities.

Key Figures

Q2 net product revenue: approximately $45 million Gross margin: approximately 35% Sales guidance: $140-$150 million +5 more

Q2 net product revenue

approximately $45 million

Q2 2026 AUCATZYL

Gross margin

approximately 35%

year-to-date FY 2026

Sales guidance

$140-$150 million

FY 2026, increased from $120-$135 million

Sequential sales growth

approximately 70%

Q2 2026 versus Q1 2026

Year-over-year sales growth

more than 100%

Q2 2026 versus Q2 2025

Credit facility

up to $250 million

five-year senior credit facility with Perceptive Advisors

Initial funding

$75 million

principal amount issued at closing

Warrant

up to 3.5 million ADSs at $1.9314 per ADS

issued to Perceptive at facility closing

Historical Context

5 past events · Latest: Jul 01

5 events

1. Jul 01

   Inducement grants

   24h Move

   +0.0%

   Equity awards granted to 13 new employees under the inducement plan

2. Jun 25

   Investor conference

   24h Move

   +0.0%

   Company announced participation in the H.C. Wainwright virtual conference

3. Jun 12

   Biotechnology award

   24h Move

   +0.0%

   Company received the 2026 Prix Galien UK Award for Best Biotechnology Product

4. May 27

   Investor conferences

   24h Move

   +0.0%

   Company announced participation in two investor conferences in early June

5. May 21

   Clinical data update

   24h Move

   +3.0%

   ASCO update reported remission and response-duration data from the FELIX study

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

senior credit facility, SOFR, interest-only, VWAP, +1 more

5 terms

senior credit facility financial

"a five-year, interest-only senior credit facility"

A senior credit facility is a large loan or revolving line of credit that a company borrows from banks or lenders and that has first claim on the company’s cash and assets if the business runs into financial trouble. Think of it as the “first in line” debt with stronger repayment priority and usually stricter rules, so investors watch it because its size, cost and covenants affect a company’s cash flow, risk profile and the value of equity and other creditors.

SOFR financial

"the one month secured overnight financing rate (“SOFR”)"

The Secured Overnight Financing Rate (SOFR) is a market benchmark that measures the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Investors watch SOFR because it acts like a speedometer for short-term interest costs—affecting loan rates, bond yields and the pricing of interest-rate contracts—so movements change borrowing expenses, cash returns and the value of interest-sensitive investments.

interest-only financial

"will be interest-only until maturity"

A loan or payment plan where the borrower pays only the interest for a set period while the original loan amount (the principal) stays unchanged; after that period payments typically rise to cover principal or a lump-sum principal payment is due. For investors this matters because interest-only structures change cash flows and risk: they can boost short-term income but increase the chance of payment shock or default later, similar to renting a car without paying down the purchase cost until the final bill arrives.

VWAP financial

"equal to 125% of the 30-day VWAP"

VWAP, or Volume-Weighted Average Price, is a way to find the average price of a stock throughout the trading day, giving more importance to times when more shares are traded. It helps traders see the typical price and decide whether a stock is expensive or cheap compared to its average, similar to finding the average speed during a trip by giving more weight to times when you traveled faster or slower.

lymphoblastic leukemia medical

"core adult lymphoblastic leukemia (ALL) commercial business"

A cancer of the blood and bone marrow in which immature white blood cells called lymphoblasts multiply uncontrollably, crowding out normal blood cells and impairing the immune system. It matters to investors because its diagnosis, treatment advances, clinical trial results, regulatory approvals, and epidemiology can materially affect the prospects and valuation of pharmaceutical, biotech, diagnostics, and healthcare service companies working on therapies or tests for the disease.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date
• FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million
• Capital base strengthened through five-year, interest-only credit facility with $75 million funded at close
• Autolus to report Q2 2026 financial results on August 11, 2026

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date. Autolus also announced that it has entered into a strategic financing with Perceptive Advisors (“Perceptive”), a leading global healthcare specialist investor, for the sale of notes of up to $250 million in aggregate principal amount in a five-year, interest-only senior credit facility (the “Credit Facility”), subject to certain conditions. An initial $75 million principal amount of notes has been issued by Autolus to Perceptive on July 30, 2026, and an additional $25 million in aggregate principal amount will be available at Autolus’ option for up to six months post-closing. An additional $150 million in aggregate principal amount of subsequent capital may become available in separate tranches upon achievement of certain pre-specified revenue milestones.   

“In the second quarter, AUCATZYL sales increased approximately 70% over Q1 2026 and more than 100% compared to Q2 2025. The strong sales growth is driven by expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online. Physician adoption of AUCATZYL is underscored by the real-world experience reported by the ROCCA consortium earlier in the year,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “The increased product volumes, combined with the ongoing operational efficiency initiatives announced in April 2026, together drove a significant step up in gross margin from a negative gross margin of approximately 20% in the second half of 2025 to a positive gross margin of approximately 35% in the first half of 2026. We expect gross margin to continue to improve.”

“The strategic financing with Perceptive Advisors provides us with additional capital to support key inflection points for the business, including clinical data milestones in our oncology and autoimmune development programs, and is underpinned by the positive sales and gross margin development from our core adult lymphoblastic leukemia (ALL) commercial business,” said Rob Dolski, Chief Financial Officer of Autolus. “With obe-cel’s unique profile we have a meaningful opportunity to expand into new and larger markets which we view as significant growth drivers. The potential additional tranches in this financing, if drawn down, provide optionality and flexibility to invest in these larger autoimmune indications.”

“Our goal is to support technologies that carry a meaningful opportunity to help patients, and we are pleased to partner with Autolus in their mission to deliver obe-cel to people with cancer and autoimmune diseases. With this facility, we are providing flexible growth capital to enable the Company to deliver on its strategic priorities and catalyze value creation,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “This financing reflects our confidence in the leadership team at Autolus to continue to deliver on obe-cel’s commercial and development plans.”

The Credit Facility will bear interest at a rate per annum equal to the one month secured overnight financing rate (“SOFR”) (subject to a SOFR floor of 3.50%), plus 7.25%, and will be interest-only until maturity. Interest margin reductions may become available upon achievement of certain revenue milestones. At closing of the Credit Facility, Autolus issued Perceptive a warrant to purchase up to 3.5 million American Depositary Receipts (ADSs), each ADS representing one ordinary share, at an exercise price of $1.9314 per ADS, equal to 125% of the 30-day VWAP immediately preceding the closing date.

The combined first and second tranches from the Credit Facility, totaling $100 million in aggregate principal amount, together with Autolus’ most recently reported cash, cash equivalents and marketable securities, provide funding into Q2 2028, and are expected to allow the Company to deliver on key strategic priorities.

Autolus will report full second quarter 2026 financial results on August 11, 2026. Further information on the terms of the credit facility can be found in the Company’s filings with the U.S. Securities and Exchange Commission in connection with the Credit Facility.

Jefferies International Limited acted as debt advisor and Cooley served as legal advisor to Autolus Therapeutics in connection with the Credit Facility. Latham & Watkins served as legal advisor to Perceptive.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Cautionary Note Regarding Forward-Looking Statements  
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects, including guidance on 2026 AUCATZYL net product revenue and improvement in gross margin, and the impact of recently announced restructuring activities; the impact of the Credit Facility on Autolus’ anticipated cash runway; Autolus’s ability to achieve the milestones under the Credit Facility, including with respect to the availability of the remaining tranches of the Credit Facility and interest margin reductions; the therapeutic potential and expected clinical benefits of AUCATZYL for adult patients with r/r B-ALL and obe-cel in additional indications including LN and progressive MS; Autolus’s ability to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof; expectations regarding the commercialization, marketing and manufacturing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories; the development of obe-cel in autoimmune indications and of additional product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work; the period during which the results of clinical studies or trials will become available; Autolus’ plans to expand, develop and enhance its manufacturing activities; and Autolus’ pursuit of expanded market access across Europe. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks identified in the section titled "Risk Factors" in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC), on March 27, 2026 and any of its subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the SEC. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus’ views as of any date subsequent to the date of this press release.

Contact:  

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Autolus Therapeutics' preliminary Q2 2026 AUCATZYL revenues (NASDAQ: AUTL)?

Autolus reported preliminary Q2 2026 AUCATZYL net product revenue of about $45 million. According to Autolus, this reflects approximately 70% growth versus Q1 2026 and more than 100% growth compared to Q2 2025, driven by higher use at existing and new treatment centers.

How did Autolus Therapeutics change its 2026 sales guidance for AUCATZYL (AUTL)?

Autolus increased its full-year 2026 AUCATZYL sales guidance to $140–$150 million. According to Autolus, this is up from the prior range of $120–$135 million and is supported by strong Q2 2026 revenue growth and improving gross margins in the first half of 2026.

What are the key terms of Autolus Therapeutics' $250 million credit facility with Perceptive Advisors?

Autolus entered a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. According to Autolus, $75 million funded at close, $25 million is available for six months, and up to $150 million more may be drawn upon achieving specified revenue milestones.

What interest rate will Autolus Therapeutics pay on its new Perceptive Advisors loan?

The credit facility will bear interest at one-month SOFR plus 7.25% per year, with a SOFR floor of 3.50%. According to Autolus, the facility is interest-only until maturity, and interest margin reductions may occur if certain revenue milestones are achieved.

How long is Autolus Therapeutics funded following the new credit facility (NASDAQ: AUTL)?

Autolus expects funding into Q2 2028 using the first two tranches of the facility and existing cash. According to Autolus, the combined $100 million in debt capacity plus its most recently reported cash and investments should support key strategic priorities over this period.

Does the Perceptive Advisors financing involve potential equity dilution for Autolus shareholders?

Yes, Autolus issued Perceptive a warrant to buy up to 3.5 million ADSs at $1.9314 each. According to Autolus, this strike price equals 125% of the 30-day volume-weighted average price immediately before closing, creating potential future share issuance if exercised.

When will Autolus Therapeutics report full Q2 2026 financial results?

Autolus plans to report its full Q2 2026 financial results on August 11, 2026. According to Autolus, the preliminary figures released now cover AUCATZYL net product revenue, gross margin trends, and updated 2026 sales guidance ahead of the detailed quarterly report.